Show simple item record

dc.contributor.authorShireen, R
dc.contributor.authorBrennan, D
dc.contributor.authorFlannelly, G
dc.contributor.authorFennelly, D
dc.contributor.authorLenehan, P
dc.contributor.authorFoley, M
dc.date.accessioned2012-04-24T13:33:05Z
dc.date.available2012-04-24T13:33:05Z
dc.date.issued2012-02
dc.identifier.citationSurvival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. 2012, 105 (2):47-50 Ir Med Jen_GB
dc.identifier.issn0332-3102
dc.identifier.pmid22455239
dc.identifier.urihttp://hdl.handle.net/10147/220292
dc.descriptionAdjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.en_GB
dc.description.abstractAdjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.
dc.language.isoenen
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.subject.meshAdenocarcinoma
dc.subject.meshAdenocarcinoma, Mucinous
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshCystadenocarcinoma, Serous
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshNeoplasm, Residual
dc.subject.meshOvarian Neoplasms
dc.subject.meshPaclitaxel
dc.titleSurvival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Obstetrics, National Maternity Hospital, Holles St., Dublin 2.en_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinsteren
refterms.dateFOA2018-08-22T16:36:08Z
html.description.abstractAdjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.


Files in this item

Thumbnail
Name:
Article6277.pdf
Size:
16.70Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record